Preliminary trial of adjuvant surgery for advanced gastric cancer

Oncology Letters

Volumn 1, Issue 4, 2010, Pages 743-747

  Suzuki, T ^a   Tanabe, K ^a   Taomoto, J ^b   Yamamoto, H ^a   Tokumoto, N ^a   Yoshida, K ^c   Ohdan, H ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA CITY ASA HOSPITAL   (Japan)

^c GIFU UNIVERSITY   (Japan)

Author keywords

Adjuvant surgery; Docetaxel; Gastric cancer; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; DEXAMETHASONE; DOCETAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GASTRECTOMY; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; OVERALL SURVIVAL; STOMACH CANCER; TREATMENT RESPONSE;

EID: 77954945938     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol_00000130     Document Type: Article

References (28)

1. Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across fve continents: defning priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150, 2006.
2. Inoue M and Tsugane S: Epidemiology of gastric cancer in Japan. Postgrad med J 81: 419-424, 2005.
3. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA and Rausch M: Modifed therapy with 5-fuorouracil, doxoru-bicin, and methotrexate in advanced gastric cancer. Cancer 72: 37-41, 1993.
4. Glimelius B, Ekstrom K, Hoffman K, et al: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8: 163-168, 1997.
5. MacDonald JS, Schein PS, Woolley PV, et al: 5-fuorouracil, doxorubicin, and mitomycin (fam) combination chemotherapy for advanced gastric cancer. Ann Intern med 93: 533-536, 1980.
6. Findlay M, Cunningham D, Norman A, et al: A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fuorouracil (ECF). Ann Oncol 5: 609-616, 1994.
7. Ohtsu A, Shimada Y, Shirao K, et al: Randomized phase III trial of fuorouracil alone vs. fuorouracil plus cisplatin vs. uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21: 54-59, 2003.
8. Koizumi W, Narahara H, Hara T, et al: S-1 plus cisplatin vs. S-1 alone for frst-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 9: 215-221, 2008.
9. Boku N, Yamamoto S, Fukuda H, et al: Fluorouracil vs. combination of irinotecan plus cisplatin vs. S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10: 1063-1069, 2009.
10. Einzig AI, Neuberg D, Remick SC, et al: Phase II trial of docetaxel (taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol e1293. med Oncol 13: 87-93, 1996.
11. Thuss-Patience PC, Kretzschmar A and Reichardt P: Docetaxel in the treatment of gastric cancer. Future Oncol 2: 603-620, 2006.
12. Fushida S, Fujimura T, Oyama K, Yagi Y, Kinoshita J and Ohta T: Feasibility and effcacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases. Anticancer Drugs 20: 752-756, 2009.
13. Zang DY, Yang DH, Kim MJ, et al: Dose-fnding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer. Cancer Chemother Pharmacol 64: 877-883, 2009.
14. Yoshida K, Hirabayashi N, Takiyama W, et al: Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer. Anticancer Res 24: 1843-1851, 2004.
15. Yoshida K, Ninomiya M, Takakura N, et al: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12: 3402-3407, 2006.
16. Suzuki T, Yoshida K, Tanabe K, et al: Three advanced gastric cancer patients successfully treated by combination therapy of docetaxel and TS-1. Gan To Kagaku Ryoho 32: 509-513, 2005.
17. Tsutani Y, Ohara M, Suzuki T, et al: Docetaxel and S-1 as a frst-line treatment in patients with advanced or recurrent gastric cancer. Anticancer Res 29: 2775-2779, 2009.
18. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
19. Japanese Gastric Cancer Association: Japanese classifcation of gastric carcinoma - 2nd english edition. Gastric Cancer 1: 10-24, 1998.
20. Trotti A, Colevas AD, Setser A, et al: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181, 2003.
21. Tanabe K, Yoshida K, Hamai Y, et al: Clinical study of TS-1 for inoperative and recurrent gastric cancer and evaluation of long survival cases. Gan To Kagaku Ryoho 32: 1145-1148, 2005.
22. Van Den Neste E, de Valeriola D, Kerger J, et al: A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fuorouracil in patients with advanced solid tumors. Clin Cancer Res 6: 64-71, 2000.
23. Takahashi I, Emi Y, Kakeji Y, Uchida J, Fukushima m and maehara Y: Increased antitumor activity in combined treatment TS-1 and docetaxel. A preclinical study using gastric cancer xenografts. Oncology 68: 130-137, 2005.
24. Wada Y, Yoshida K, Suzuki T, et al: Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fuorouracil in human gastric cancer cell lines. Int J Cancer 119: 783-791, 2006.
25. Koizumi W, Tanabe S, Saigenji K, et al: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89: 2207-2212, 2003.
26. Nakajima T, Ota K, Ishihara S, et al: Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol 4: 203-208, 1997.
27. Chua YJ and Cunningham D: The UK NCRI mAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice. Ann Surg Oncol 14: 2687-2690, 2007.
28. Alexander HR, Grem JL, Pass HI, et al: Neoadjuvant chemotherapy for locally advanced gastric adenocarcinoma. Oncology (Williston Park) 7: 37-53, 1993.